Long-Term Follow-Up of Children with Cardiac Disease Requiring Mechanical Circulatory Support

2000 ◽  
Vol 69 (1) ◽  
pp. 186-192 ◽  
Author(s):  
Andra E Ibrahim ◽  
Brian W Duncan ◽  
Elizabeth D Blume ◽  
Richard A Jonas

2017 ◽  
Vol 18 (2) ◽  
pp. 176-182 ◽  
Author(s):  
Thilo P. K. Fleck ◽  
Georg Dangel ◽  
Felix Bächle ◽  
Christoph Benk ◽  
Jochen Grohmann ◽  
...  

2015 ◽  
Vol 149 (6) ◽  
pp. e115-e116 ◽  
Author(s):  
Evgenij V. Potapov ◽  
Tomohiro Saito ◽  
Alain Carpentier ◽  
Roland Hetzer ◽  
Thomas Krabatsch

Life ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 87
Author(s):  
Khalil Jawad ◽  
Alex Koziarz ◽  
Maja-Theresa Dieterlen ◽  
Jens Garbade ◽  
Christian D. Etz ◽  
...  

Background: Peripartum cardiomyopathy (PPCM) is a rare, life-threatening form of heart disease, frequently associated with gene alterations and, in some cases, presenting with advanced heart failure. Little is known about ventricular assist device (VAD) implantation in severe PPCM cases. We describe long-term follow-up of PPCM patients who were resistant to medical therapy and received mechanical circulatory support or heart transplant. Methods and results: A total of 13 patients were included with mean follow-up of eight years. Mean age of PPCM onset was 33.7 ± 7.7 years. All patients were initially treated with angiotensin-converting enzyme inhibitors and beta-blockers, and four received bromocriptine. Overall, five patients received VADs (three biventricular, two isolated left ventricular) at median 27 days (range: 3 to 150) following childbirth. Two patients developed drive line infection. Due to the short support time, none of those patients had a stroke or VAD thrombosis. In total, five patients underwent heart transplantation, of which four previously had implanted VADs. Median time to transplantation from PPCM onset was 140 days (range: 43 to 776), and time to transplantation from VAD implantation were 7, 40, 132, and 735 days, respectively. All patients survived until most recent follow up, with the exception of one patient who died following unrelated abdominal surgery two years after PPCM recovery. Conclusions: In patients with severe, life-threatening PPCM refractory to medical management, mechanical circulatory support with or without heart transplantation is a safe therapeutic option.


ASAIO Journal ◽  
1988 ◽  
Vol 34 (2) ◽  
pp. 116-124 ◽  
Author(s):  
Shelly A. Ruzevich ◽  
Kirk R. Kanter ◽  
D Glenn Pennington ◽  
Marc T. Swartz ◽  
Lawrence R. McBride ◽  
...  

2008 ◽  
Vol 17 (7) ◽  
pp. 634-639 ◽  
Author(s):  
Taiji Murakami ◽  
Hironobu Nakayama ◽  
Hiroyuki Irie ◽  
Koichi Kino ◽  
Kunikazu Hisamochi ◽  
...  

Author(s):  
Nicholas Hess ◽  
Yisi Wang ◽  
Arman Kilic

Background: This study evaluated the utilization and outcomes of postcardiotomy mechanical circulatory support (MCS). Methods: This was a retrospective, single institution analysis of adult cardiac surgery cases that required de novo MCS following surgery from 2011-2018. Patients that were bridged with MCS to surgery were excluded. The primary outcomes were early operative mortality and longitudinal survival. Secondary outcomes included postoperative complications, and five-year all-cause readmission. Results: 533 patients required de novo postcardiotomy MCS, with the most commonly performed procedure being isolated coronary artery bypass grafting (29.8%). Median cardiopulmonary bypass and cross clamp times were 185 (IQR 123-260) minutes and 122 (IQR 81-179) minutes, respectively. A total of 442 (82.9%) of patients were supported with intra-aortic balloon pump counterpulsation, 23 (4.3%) with an Impella device, and 115 (21.6%) with extracorporeal membrane oxygenation. Three (0.6%) patients had an unplanned ventricular assist device placed. Operative mortality was 29.8%. Longitudinal survival was 56.1% and 43.0% at 1- and 5-years, respectively. Survival was lowest in those supported with ECMO and highest with those supported with an Impella (P<0.001). Freedom from readmission was 61.4% at 5-years. Postoperative ECMO was an independent predictor of mortality (HR 5.1, 95% CI 2.0-12.9, P<0.001), but none of the MCS types predicted long-term hospital readmission after risk adjustment. Conclusions: Postcardiotomy MCS is associated with high operative mortality. Even patients that survive to discharge have compromised longitudinal survival, with nearly only half surviving to 1-year. Close follow-up and early referral to advanced heart failure specialists may be prudent in improving these outcomes.


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
G Hatzis ◽  
H Ahrens ◽  
K Karatolios ◽  
B Markus ◽  
D Divchev ◽  
...  

Abstract Background Although the use of mechanical circulatory support (MCS) systems may improve the outcome of patients with cardiogenic shock (CS) due to myocardial infarction, little is known about its effect on the long-term structural integrity of left-ventricular (LV) valves as well as on the development of LV- architecture. Methods 84 consecutive patients were monitored over 2 years having received microaxillar MCS device (ImpellaTM CP or 2.5) for complete coronary revascularization followed by optimal medical treatment. Results 62 patients were treated for severe cardiogenic shock and compared with 22 patients receiving short-term microaxillar MCS for high risk percutaneous coronary interventions (PCI). 24 patients of the total population received Impella CP (14F motor pump) and the remaining 60 patients received Impella 2.5 (12F motor pump). Beside a significant increase in LV-ejection fraction after 2 years (p≤0.03 vs. pre implantation) in total cohort, we observed a statistically significant decrease in LV-dilation (p&lt;0.001) and the severity of mitral valve regurgitation (p=0.007) in the 2 year follow-up period suggesting an improved LV-architecture. Neither the duration of support, nor the size of the MCS device or the indication for its use revealed any devastating impact on aortic or mitral valve integrity. Conclusions These findings indicate that beside complete revascularization and optimal medical treatment, microaxillar transvalvular MCS device supports the restoration of LV-architecture without detrimental long-term effects on the structural integrity of LV valves regardless of the size of the device or the duration of support. Funding Acknowledgement Type of funding source: None


Sign in / Sign up

Export Citation Format

Share Document